Cargando…
[(18)F]FE-PE2I PET is a feasible alternative to [(123)I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism
BACKGROUND: Dopamine transporter (DAT) imaging of striatum is clinically used in Parkinson’s disease (PD) and neurodegenerative parkinsonian syndromes (PS) especially in the early disease stages. The aim of the present study was to evaluate the diagnostic performance of the recently developed tracer...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452620/ https://www.ncbi.nlm.nih.gov/pubmed/36070114 http://dx.doi.org/10.1186/s13550-022-00930-x |
_version_ | 1784784948674166784 |
---|---|
author | Marner, Lisbeth Korsholm, Kirsten Anderberg, Lasse Lonsdale, Markus N. Jensen, Mads Radmer Brødsgaard, Eva Denholt, Charlotte L. Gillings, Nic Law, Ian Friberg, Lars |
author_facet | Marner, Lisbeth Korsholm, Kirsten Anderberg, Lasse Lonsdale, Markus N. Jensen, Mads Radmer Brødsgaard, Eva Denholt, Charlotte L. Gillings, Nic Law, Ian Friberg, Lars |
author_sort | Marner, Lisbeth |
collection | PubMed |
description | BACKGROUND: Dopamine transporter (DAT) imaging of striatum is clinically used in Parkinson’s disease (PD) and neurodegenerative parkinsonian syndromes (PS) especially in the early disease stages. The aim of the present study was to evaluate the diagnostic performance of the recently developed tracer for DAT imaging [(18)F]FE-PE2I PET/CT to the reference standard [(123)I]FP-CIT SPECT. METHODS: Ninety-eight unselected patients referred for DAT imaging were included prospectively and consecutively and evaluated with [(18)F]FE-PE2I PET/CT and [(123)I]FP-CIT SPECT on two separate days. PET and SPECT scans were categorized independently by two blinded expert readers as either normal, vascular changes, or mixed. Semiquantitative values were obtained for each modality and compared regarding effect size using Glass’ delta. RESULTS: Fifty-six of the [(123)I]FP-CIT SPECT scans were considered abnormal (52 caused by PS, 4 by infarctions). Using [(18)F]FE-PE2I PET/CT, 95 of the 98 patients were categorized identically to SPECT as PS or non-PS with a sensitivity of 0.94 [0.84–0.99] and a specificity of 1.00 [0.92–1.00]. Inter-reader agreement for [(18)F]FE-PE2I PET with a kappa of 0.97 [0.89–1.00] was comparable to the agreement for [(123)I]FP-CIT SPECT of 0.96 [0.76–1.00]. Semiquantitative values for short 10-min reconstructions of [(18)F]FE-PE2I PET/CT were comparable to longer reconstructions. The effect size for putamen/caudate nucleus ratio was significantly increased using PET compared to SPECT. CONCLUSIONS: The high correspondence of [(18)F]FE-PE2I PET compared to reference standard [(123)I]FP-CIT SPECT establishes [(18)F]FE-PE2I PET as a feasible PET tracer for clinical use with favourable scan logistics. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13550-022-00930-x. |
format | Online Article Text |
id | pubmed-9452620 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-94526202022-09-09 [(18)F]FE-PE2I PET is a feasible alternative to [(123)I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism Marner, Lisbeth Korsholm, Kirsten Anderberg, Lasse Lonsdale, Markus N. Jensen, Mads Radmer Brødsgaard, Eva Denholt, Charlotte L. Gillings, Nic Law, Ian Friberg, Lars EJNMMI Res Original Research BACKGROUND: Dopamine transporter (DAT) imaging of striatum is clinically used in Parkinson’s disease (PD) and neurodegenerative parkinsonian syndromes (PS) especially in the early disease stages. The aim of the present study was to evaluate the diagnostic performance of the recently developed tracer for DAT imaging [(18)F]FE-PE2I PET/CT to the reference standard [(123)I]FP-CIT SPECT. METHODS: Ninety-eight unselected patients referred for DAT imaging were included prospectively and consecutively and evaluated with [(18)F]FE-PE2I PET/CT and [(123)I]FP-CIT SPECT on two separate days. PET and SPECT scans were categorized independently by two blinded expert readers as either normal, vascular changes, or mixed. Semiquantitative values were obtained for each modality and compared regarding effect size using Glass’ delta. RESULTS: Fifty-six of the [(123)I]FP-CIT SPECT scans were considered abnormal (52 caused by PS, 4 by infarctions). Using [(18)F]FE-PE2I PET/CT, 95 of the 98 patients were categorized identically to SPECT as PS or non-PS with a sensitivity of 0.94 [0.84–0.99] and a specificity of 1.00 [0.92–1.00]. Inter-reader agreement for [(18)F]FE-PE2I PET with a kappa of 0.97 [0.89–1.00] was comparable to the agreement for [(123)I]FP-CIT SPECT of 0.96 [0.76–1.00]. Semiquantitative values for short 10-min reconstructions of [(18)F]FE-PE2I PET/CT were comparable to longer reconstructions. The effect size for putamen/caudate nucleus ratio was significantly increased using PET compared to SPECT. CONCLUSIONS: The high correspondence of [(18)F]FE-PE2I PET compared to reference standard [(123)I]FP-CIT SPECT establishes [(18)F]FE-PE2I PET as a feasible PET tracer for clinical use with favourable scan logistics. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13550-022-00930-x. Springer Berlin Heidelberg 2022-09-07 /pmc/articles/PMC9452620/ /pubmed/36070114 http://dx.doi.org/10.1186/s13550-022-00930-x Text en © The Author(s) 2022, corrected in 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Research Marner, Lisbeth Korsholm, Kirsten Anderberg, Lasse Lonsdale, Markus N. Jensen, Mads Radmer Brødsgaard, Eva Denholt, Charlotte L. Gillings, Nic Law, Ian Friberg, Lars [(18)F]FE-PE2I PET is a feasible alternative to [(123)I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism |
title | [(18)F]FE-PE2I PET is a feasible alternative to [(123)I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism |
title_full | [(18)F]FE-PE2I PET is a feasible alternative to [(123)I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism |
title_fullStr | [(18)F]FE-PE2I PET is a feasible alternative to [(123)I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism |
title_full_unstemmed | [(18)F]FE-PE2I PET is a feasible alternative to [(123)I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism |
title_short | [(18)F]FE-PE2I PET is a feasible alternative to [(123)I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism |
title_sort | [(18)f]fe-pe2i pet is a feasible alternative to [(123)i]fp-cit spect for dopamine transporter imaging in clinically uncertain parkinsonism |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452620/ https://www.ncbi.nlm.nih.gov/pubmed/36070114 http://dx.doi.org/10.1186/s13550-022-00930-x |
work_keys_str_mv | AT marnerlisbeth 18ffepe2ipetisafeasiblealternativeto123ifpcitspectfordopaminetransporterimaginginclinicallyuncertainparkinsonism AT korsholmkirsten 18ffepe2ipetisafeasiblealternativeto123ifpcitspectfordopaminetransporterimaginginclinicallyuncertainparkinsonism AT anderberglasse 18ffepe2ipetisafeasiblealternativeto123ifpcitspectfordopaminetransporterimaginginclinicallyuncertainparkinsonism AT lonsdalemarkusn 18ffepe2ipetisafeasiblealternativeto123ifpcitspectfordopaminetransporterimaginginclinicallyuncertainparkinsonism AT jensenmadsradmer 18ffepe2ipetisafeasiblealternativeto123ifpcitspectfordopaminetransporterimaginginclinicallyuncertainparkinsonism AT brødsgaardeva 18ffepe2ipetisafeasiblealternativeto123ifpcitspectfordopaminetransporterimaginginclinicallyuncertainparkinsonism AT denholtcharlottel 18ffepe2ipetisafeasiblealternativeto123ifpcitspectfordopaminetransporterimaginginclinicallyuncertainparkinsonism AT gillingsnic 18ffepe2ipetisafeasiblealternativeto123ifpcitspectfordopaminetransporterimaginginclinicallyuncertainparkinsonism AT lawian 18ffepe2ipetisafeasiblealternativeto123ifpcitspectfordopaminetransporterimaginginclinicallyuncertainparkinsonism AT friberglars 18ffepe2ipetisafeasiblealternativeto123ifpcitspectfordopaminetransporterimaginginclinicallyuncertainparkinsonism |